[Phase II study on oral administration of MCNU (ranomustine) tablet. Hanshin Cooperative Study Group on Hematological Disorders].

Abstract

A phase II study of MCNU tablet has been performed on 70 patients with hematological disorders including mostly myeloproliferative disorders. MCNU tablet was given p.o. at a dose of 50 mg daily for 2-6 days (total 100-300mg) as one course with average intervals of 3 to 5 months or more for patients responding to this drug. The effective rates were 72% in 18 patients with chronic myelogenous leukemia, 88% in 25 patients with polycythemia vera and 68.5% in 19 patients with essential thrombocythemia. Side effects of MCNU tablet were nausea and vomiting (31%) which had a dose-dependent relationship, mild liver dysfunction (5%) and elevation of BUN and creatinine (2%) which were not serious. The results were almost comparable to those of the phase II study of MCNU given intravenously.

• Authors: A Kanamaru, K Nagai, T Masaoka, H Shibata, T Kitani, N Taniguchi, A Horiuchi, K Tsubaki, H Kawagoe, M Hirata
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 13 Issue 5 Pg. 1915-20 (May 1986) ISSN: 0385-0684 [Print] Japan
• PMID: 3458432 (Publication Type: English Abstract, Journal Article)

Chemical References

• Antineoplastic Agents
• Nitrosourea Compounds
• Tablets
• ranimustine

Topics

• Administration, Oral
• Adult
• Aged
• Antineoplastic Agents (therapeutic use)
• Drug Administration Schedule
• Female
• Hematologic Diseases (drug therapy)
• Humans
• Leukemia, Myeloid (drug therapy)
• Male
• Middle Aged
• Nitrosourea Compounds (therapeutic use)
• Polycythemia (drug therapy)
• Tablets
• Thrombocytosis (drug therapy)